| Methods |
Study design: RCT; 26% of total study population had type 2 diabetesRandomization procedure: NRAllocation concealment: UnclearFollow‐up: 54w |
| Participants |
Country: SwedenSetting: 33 primary care centersNumber: 99Age: 54y (whole population)Sex: 64% (whole population)Medications: NRBL wt: NR for diabetic populationBL BMI: NR for diabetic populationBL GHb: I 8.7, C 10.0 |
| Interventions |
Drug: OrlistatDosage: 120mg tidDuration: 52wDiet: 600kcal/d deficitComparison: Placebo + diet |
| Outcomes |
Weight: YesBMI:>5% loss (%): YesFBS: YesGHb: YesCholesterol:LDL:HDL:TG:SBP:DBP:Side effects: Yes |
| Notes |
Funding: Roche AB, Stockholm, SwedenAbstract/full text: FTLOCF: NRITT: Yes, with attritionAttrition: 14%Blinding: Double‐blindBlinding assessor: UnclearBL comparable: Yes (for whole population)Jadad score: 1,1,1,B Risk of bias: B |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
